Changchun BCHT Biotech In-Licenses RSV Vaccine from Mucosis

Changchun BCHT Biotechnology signed a long-term collaboration and licensing deal with Dutch vaccine company Mucosis B.V. The agreement is part of a $6.9 million funding round for Mucosis, in which BCHT participated. For its investment, BCHT received a China license to Mucosis’ SynGEM® prefusion F vaccine candidate for RSV and its Mimopath® platform for other disease targets. In addition to the equity investment, BCHT will also make “customary” payments including royalties. More details.... Share this with colleagues: // //